对于食道癌症的新辅助疗法后,他类药物的使用和瘤结果
Dillen C van der Aa1,2, Maarten C J Anderegg1,2, Jacques J G H M Bergman3,4
1Department of Surgery, Amsterdam UMC, Location University of Amsterdam, Amsterdam, The Netherlands.
Journal of thoracic disease
|March 12, 2026
概括
这项研究发现,使用他类药物并没有改善接受新辅助治疗的食道癌患者的治疗结果. 基于这些发现,对于食道癌症治疗,不应改变他类药物治疗.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
背景情况:
- 用于高胆固醇血症的他类药物显示出临床前的抗癌作用.
- 它们在食道癌治疗中的作用尚未得到充分证实.
- 这项研究调查了他类药物对食道癌症新辅助治疗结果的影响.
研究的目的:
- 评估他类药物治疗对病理完整响应 (pCR) 率的影响.
- 评估他类药物使用对无病生存期 (DFS) 和整体生存期 (OS) 的影响.
- 确定他类药物是否会影响接受新辅助治疗和手术的食道癌患者的结果.
主要方法:
- 对463名接受新辅助疗法和食道切除术的食道癌患者的回顾性分析.
- 统计剂使用者 (90名患者) 和非使用者 (373名患者) 之间的结局比较.
- 分析包括新辅助化疗 (CT) 和化疗放射治疗 (CRT) 方案.
主要成果:
- 在他类药物使用者 (22.2%) 和非使用者 (17.4%) 之间,pCR率没有显著差异.
- 中位数的DFS (45个月与40个月) 和OS (44个月与42个月) 并没有显著差异.
- 在使用脂性他类药物的腺癌患者中观察到改善DFS的趋势.
结论:
- 在这种食道癌队列中,使用他类药物与改善的病理反应或存活率无关.
- 研究结果不支持在接受新辅助治疗的食道癌症患者改变他类药物治疗.
- 进一步的研究可能会在食道腺癌中探索特定的他类型.
相关概念视频
Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
Barrett Esophagus-II: Clinical Manifestations and Management
1.4K
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
1.4K
Esophageal Strictures-II: Clinical Features and Management
841
Patients with esophageal strictures often experience a range of symptoms. Initially, they may have difficulty swallowing solid foods, which can progress to include liquids. Additional symptoms may involve chest pain or discomfort, regurgitating food and fluids, heartburn, unintentional weight loss, coughing or choking during meals, and hoarseness.
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
841
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
763
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
763
Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Esophageal Varices-I: Introduction
1.9K
Esophageal varices are dilated, tortuous veins which are found mainly in the submucosa of the lower esophagus but which may also appear higher up or extend into the stomach. They develop due to increased pressure in the portal venous system, often as a result of liver cirrhosis. This condition scars and damages the liver, impeding normal blood flow through the portal vein. To compensate, blood seeks alternative pathways, forming fragile new vessels (varices) in the esophagus and stomach. These...
1.9K


